Human Accell siRNA Library - Druggable Genome

Targeted gene silencing in difficult-to-transfect cells. Accell siRNA permits RNAi screening in difficult-to-transfect cells with no transfection reagent, virus, or electroporation.


An arrayed siRNA collection targeting human genes that are potential therapeutic targets.

The Accell Druggable Genome library contains the genes that are considered potential targets for therapeutics, including kinases, proteases, phosphatases, GPCRs, ion channels, ubiquitin ligases, and genes involved in senescence, autophagy, DNA repair, and characterized nuclear receptors, This extensive library is delivered as nine distinct subset siRNA libraries in the 96-well format. In the 384-well format the first eight subsets are plated continuously to reduce partial plates.

Accell siRNA achieves what no other RNAi product can claim: delivery into difficult-to-transfect cells without transfection reagents, virus, or electroporation. Researchers around the world are achieving targeted gene silencing in cells that had previously been beyond the reach of conventional RNAi products due to toxicity caused by transfection reagents or undesirable viral responses.

Highlights

  • Accell siRNA enters cells without the need for transfection reagents, virus (or viral vectors), or instruments
  • Proven performance in neuronal, immunological, primary, and other difficult-to-transfect cell types
  • Extended-duration knockdown with optimized continuous application
  • Available as SMARTpool siRNA reagents or a Set of 4 siRNAs in 96 or 384-well plates

 

Nine subsets make up the human druggable genome siRNA Library

 

  • GPCR
  • Protein Kinases
  • Ion Channels
  • Phosphatases
  • Drug Targets- Includes genes involved with apoptosis, senesence, nucleic acid binding, autophagy, DNA repair, and characterized nuclear receptors.
  • Proteases
  • Ubiquitin Conjugation 1 - Cullins, E1, E2, HECT E3 Ligases
  • Ubiquitin Conjugation 2 - F-box, SOCS box E3 Ligases
  • Ubiquitin Conjugation 3 - RING finger and RING finger-like E3 Ligases
 
Experimental Considerations

 

  • Accell siRNA works at a higher concentration than conventional siRNA; recommended 1 µM working concentration
  • Delivery may be inhibited by the presence of BSA in serum. Optimization studies with serum-free media formulations (Accell Delivery Media) or < 2.5% serum in standard media is recommended
  • Full-serum media can be added back after 48 hours of incubation. Optimal mRNA silencing is typically achieved by 72 hours or up to 96 hours for protein knockdown

 

  
HazardousNo
Shelf Life12 Months
Shipping ConditionAmbient
Storage Condition-20 C
Drug Targets make up part of Druggable Genome Collection

Drug Targets make up part of Druggable Genome Collection

Drug Targets make up part of Druggable Genome Collection

The Drug Targets siRNA library consists of high-confidence gene targets based on publications that characterize potential druggable targets and was assembled with use of innovative bioinfomatics tools to analyze genetic and ontological information from multiple databases. This siRNA collection excludes gene targets available in other siRNA libraries: kinases, g-protein coupled receptors, proteases, phosphatases, ion channels, and genes involved with ubiquitin conjugation.


Cell types demonstrating effective silencing with Accell siRNA

Cell types demonstrating effective silencing with Accell siRNA

Cell types demonstrating effective silencing with Accell siRNA

Internal validation and peer-reviewed publications report numerous successes with difficult-to-transfect cell types. See the References tab for a list of publications.


The Accell siRNA application protocol simplifies targeted gene knockdown

The Accell siRNA application protocol simplifies targeted gene knockdown

The Accell siRNA application protocol simplifies targeted gene knockdown

(1) Combine Accell siRNA with Accell delivery media (or other low- or no-serum media). (2) Add Accell delivery mix directly to cells, and incubate for 72 hours.


References

  1. B.D. Parsons, A. Schindler, D.H. Evans, E. Foley, A direct phenotypic comparison of siRNA pools and multiple individual duplexes in a functional assay. PLoS One. 4(12), e8471 (2009).
  2. M. Jiang, R. Instrell, B. Saunders, H. Berven, M. Howell, Tales from an academic RNAi screening facility; FAQs. Brief Funct. Genomics. 10(4), 227-237 (2011). [doi: 10.1093/bfgp/elr016]

Citations

  1. Click to view a more comprehensive list of Accell siRNA citations.
  2. S. Suzuki et al.Differential Roles of Epac in Regulating Cell Death in Neuronal and Myocardial CellsJ. Biol. Chem285, 24248-24259 (July 2010). [primary mouse cortical neurons (E15-17)]
  3. U. Dreses-Werringloer et al.A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Ab Levels, and Alzheimer’s Disease Risk. Cell. 133, 1149-1161 (27 June 2008). [SHSY-5Y; human neuroblastoma]
  4. S. Byas et al.Human Embryonic Stem Cells Maintain Pluripotency after E-Cadherin Expression Knockdown. FASEB J. 24, lb172 (Apr 2010). [H9 stem cell lines]
  5. V. Saini et al.CXC Chemokine Receptor 4 Is a Cell Surface Receptor for Extracellular Ubiquitin. J. Biol. Chem.  285, 15566-15576 (May 2010). [THP-1 monocytes]
  6. D. Smirnov et al.Genetic Analysis of Radiation-induced Changes in Human Gene Expression. Nature. 459, 10.1038/nature07940 (28 May 2009). [immortalized B cells]